GeNeuro SA (GNRO.PA)
EUR 0.08
(6.38%)
EUR 0.08
(6.38%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.91 Million EUR | 257.65% |
| 2022 | -3.74 Million EUR | 12.07% |
| 2021 | -4.26 Million EUR | 21.85% |
| 2020 | -5.45 Million EUR | -348.17% |
| 2019 | 2.19 Million EUR | 940.13% |
| 2018 | 211.33 Thousand EUR | 35.91% |
| 2017 | 155.49 Thousand EUR | 4.49% |
| 2016 | 148.81 Thousand EUR | -5.6% |
| 2015 | 157.64 Thousand EUR | 104.95% |
| 2014 | -3.18 Million EUR | -275.1% |
| 2013 | -849.7 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | 5.91 Million EUR | 257.65% |
| 2023 Q4 | 5.91 Million EUR | 0.0% |
| 2023 Q2 | 220.2 Thousand EUR | 0.0% |
| 2022 FY | -3.74 Million EUR | 12.07% |
| 2022 Q4 | -3.74 Million EUR | 0.0% |
| 2022 Q2 | -6.13 Million EUR | 0.0% |
| 2021 Q2 | -1.54 Million EUR | 0.0% |
| 2021 Q4 | -4.26 Million EUR | 0.0% |
| 2021 FY | -4.26 Million EUR | 21.85% |
| 2020 FY | -5.45 Million EUR | -348.17% |
| 2020 Q4 | -5.45 Million EUR | 0.0% |
| 2020 Q2 | -10.01 Million EUR | 0.0% |
| 2019 FY | 2.19 Million EUR | 940.13% |
| 2019 Q2 | -9.22 Million EUR | 0.0% |
| 2019 Q4 | 2.19 Million EUR | 0.0% |
| 2018 Q2 | 15.68 Thousand EUR | 0.0% |
| 2018 FY | 211.33 Thousand EUR | 35.91% |
| 2018 Q4 | 211.33 Thousand EUR | 0.0% |
| 2017 Q2 | 192.2 Thousand EUR | 0.0% |
| 2017 FY | 155.49 Thousand EUR | 4.49% |
| 2017 Q4 | 155.49 Thousand EUR | 0.0% |
| 2016 FY | 148.81 Thousand EUR | -5.6% |
| 2016 Q4 | 148.81 Thousand EUR | 0.0% |
| 2016 Q2 | -34.19 Thousand EUR | 0.0% |
| 2015 Q4 | 157.64 Thousand EUR | 0.0% |
| 2015 FY | 157.64 Thousand EUR | 104.95% |
| 2015 Q2 | -2.86 Million EUR | 0.0% |
| 2014 FY | -3.18 Million EUR | -275.1% |
| 2014 Q4 | -3.18 Million EUR | 0.0% |
| 2013 FY | -849.7 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 927.787% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 103.008% |
| Adocia SA | 127 Thousand EUR | -4553.858% |
| Aelis Farma SA | -16.19 Million EUR | 136.502% |
| Biophytis S.A. | 2.7 Million EUR | -118.661% |
| Advicenne S.A. | 12.17 Million EUR | 51.455% |
| genOway Société anonyme | 2.97 Million EUR | -98.805% |
| IntegraGen SA | -709.74 Thousand EUR | 932.745% |
| Medesis Pharma S.A. | 1.15 Million EUR | -410.305% |
| Neovacs S.A. | -237.08 Thousand EUR | 2592.925% |
| NFL Biosciences SA | -2.27 Million EUR | 359.698% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -35.668% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 811.627% |
| Sensorion SA | 1.37 Million EUR | -328.842% |
| Theranexus Société Anonyme | 2.44 Million EUR | -141.818% |
| TME Pharma N.V. | -1.07 Million EUR | 647.766% |
| Valbiotis SA | -18.13 Million EUR | 132.584% |
| TheraVet SA | 12.78 Thousand EUR | -46129.175% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -171.119% |
| argenx SE | -1.83 Billion EUR | 100.322% |
| BioSenic S.A. | 28.04 Million EUR | 78.925% |
| Celyad Oncology SA | -6.1 Million EUR | 196.86% |
| DBV Technologies S.A. | -114.95 Million USD | 105.141% |
| Galapagos NV | -157.2 Million EUR | 103.76% |
| Genfit S.A. | -7.61 Million EUR | 177.656% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 123.536% |
| Innate Pharma S.A. | -30.71 Million EUR | 119.245% |
| Inventiva S.A. | 10.48 Million EUR | 43.651% |
| MaaT Pharma SA | -10.2 Million EUR | 157.917% |
| MedinCell S.A. | 39.5 Million EUR | 85.037% |
| Nanobiotix S.A. | -24.71 Million EUR | 123.911% |
| Onward Medical N.V. | -12.89 Million EUR | 145.838% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -313.218% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 78.214% |
| Oxurion NV | 10.71 Million EUR | 44.814% |
| Pharming Group N.V. | 99.4 Million EUR | 94.054% |
| Poxel S.A. | 44.55 Million EUR | 86.736% |
| GenSight Biologics S.A. | 16.29 Million EUR | 63.727% |
| Transgene SA | -14.4 Million EUR | 141.019% |
| Financière de Tubize SA | 78.62 Million EUR | 92.483% |
| UCB SA | 2.17 Billion EUR | 99.729% |
| Valneva SE | 82.73 Million EUR | 92.856% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 131.907% |